Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Endocrine 2NET 1Head & Neck 1

Conditions

Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 2repotrectinib 1pralsetinib 1pembrolizumab 1entrectinib 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Octreotide 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × cabozantinib × NET × Clear all
NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡